Conference abstract · 8 Oct 2018
Conference abstractPublished 5 Oct 2018
Prenatal screening with first trimester biochemistry
Sonic Healthcare, Australia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Prenatal screening for assessment of fetal development has been established for almost half a century. Our first trimester screening program includes four (4) biochemical markers: PAPP-A, FhCG, PlGF and AFP. Markers were quantified (DELFIA® DXpress; PerkinElmer) and marker MoM values calculated (LifeCycle v2.2; Perkin Elmer), using lot specific derived polynomial regression curves. Pregnancies with known outcomes included: (1) Aneuploid: Trisomy 21, Trisomy 18, Trisomy 13, Triploid, Sex chromosome aneuploidies, (2) Failed pregnancies, (3) Fetal structure: Anencephaly, Fetal growth restriction, and (4) Maternal Health: Gestational trophoblastic disease, Sub-chorionic bleeding. Reduced circulating PAPP-A level is cause for concern. Low PAPP-A level is associated with aneuploidy (Trisomy/13/18/21, Triploidy) and poor pregnancy prognosis. Similarly, a low FbhCG level is also associated with compromised pregnancy. However, an elevated FbhCG is indicative of Trisomy 21. Excessively elevated FbhCG, even in presence of normal PAPP-A levels, warrants further investigation of trophoblast cell physiology. Elevated levels of fetal derived marker (AFP) may indicate increased transplacental exchange or presence of fetal structural abnormality. Biochemical profile of viable aneuploidies such as, sex chromosome aneuploidies are not distinguishable from profiles of normal pregnancies. However, NT measurements in such pregnancies are markedly increased and may present as a cystic hygroma. PlGF, a marker of placental angiogenesis, levels are reduced in first trimester pregnancies which subsequently develop early onset pre-eclampsia and/or reduced fetal development. Whilst the combination of feto-placental derived biochemistry with ultrasonographic biometry, improves Trisomy 21 detection (to about 92-93%), the inclusion of PlGF has introduced another dimension to screening because now we can simultaneously screen for both fetal and maternal wellbeing. Over the past two decades, non-invasive prenatal screening has progressed from screening for targeted fetal abnormalities to combined prenatal assessment of feto-maternal wellbeing. Each screening modality (biochemistry, ultrasonography, cfDNA) offers benefits only attained in a holistic screening offering.
Subjects
Biochemistry & BiotechnologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract
Case report: Confirming the role of conventional combined biochemical prenatal screening in first trimester for detection of genetically affected fetuses
Research article · 4 Oct 2016
First Trimester Prenatal Care and Local Obstetrical Delivery Options for Women in Poverty in Rural Virginia
Case report · 30 Jun 2007
First-trimester prenatal diagnosis of pyruvate kinase deficiency in an Indian family with the pyruvate kinase-Amish mutation
Case report · 2015
Lessons Learned from Two Missed Prenatal Cases of Hemoglobin Barts Hydrops Fetalis Until Second Trimester Despite a Nationwide Screening Program
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectBiochemistry & Biotechnology
- BylineArticles whose byline prints “Michael J Sinosich”
